CEL-SCI Corp
$ 1.08
-2.70%
12 Jun - close price
- Market Cap 16,087,400 USD
- Current Price $ 1.08
- High / Low $ 1.15 / 1.00
- Stock P/E N/A
- Book Value 0.81
- EPS -2.15
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -3.05 %
- 52 Week High 13.48
- 52 Week Low 0.89
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-12 | 2025-12-23 | 2025-08-14 | 2025-05-14 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-16 | 2024-02-14 | 2023-12-22 | 2023-08-11 | 2023-05-12 |
| Reported EPS | -0.68 | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -4.2 | -8.4 | -4.2 | -0.16 | -5.7 | -5.7 |
| Estimated EPS | 0 | None | None | None | -3.3 | -0.1 | -3.9 | -4.2 | -4.2 | -0.16 | -4.5 | -5.1 |
| Surprise | -0.68 | 0 | 0 | 0 | 0.6 | -2.6003 | -0.3 | -4.2 | 0 | 0 | -1.2 | -0.6 |
| Surprise Percentage | None% | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | -100% | 0% | 0% | -26.6667% | -11.7647% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-06-12 11:39:31
CEL-SCI Corporation and Saudi Amarox are formalizing a strategic agreement at the BIO International Convention 2026 to commercialize and distribute Multikine in Saudi Arabia. This collaboration aligns with Saudi Arabia's Vision 2030, which aims to develop a dynamic biotechnology sector, and positions Multikine within a rapidly growing immunotherapy market in the region. The agreement includes a 50/50 revenue share and the potential for expansion into other GCC countries, highlighting the significant investment in innovative therapies in the Middle East.
2026-05-29 22:09:18
This page provides a detailed overview of Cel-Sci Corp (CVM) stock, including its latest stock price, financial data, analyst ratings, and a comprehensive list of recent corporate news and filings. It highlights the company's focus on investigational immunotherapy products for cancer and infectious diseases, particularly Multikine for head and neck cancers, and includes insider trading activity.
2026-05-27 20:40:12
CEL-SCI Corporation filed a Form RW (Withdrawal of Registration Statement) with the SEC, requesting to withdraw a Post-Effective Amendment to its Registration Statement on Form S-3. The company stated that the amendment was filed in error and no securities were sold through it. The filing lists Geert R. Kersten, Chief Executive Officer, as the signatory.
2026-05-19 04:40:18
HART & HART, LLC, representing CEL-SCI Corporation, has requested the withdrawal of a Post-Effective Amendment to a Registration Statement on Form S-3 (File No. 333-265995). The firm stated that the amendment was filed in error and no securities were sold as a result. This filing has been deemed neutral in both impact and sentiment.
2026-05-18 15:08:56
Cel Sci CEO Geert Kersten's trust, with CEO Geert R. Kersten as trustee, purchased 300,000 shares of the company's common stock for $360,000. This insider purchase comes despite the company facing challenges, including burning through cash and a significant stock decline. In other news, CEL-SCI recently completed a public offering and announced a partnership with Amarox for the commercialization of its product Multikine in Saudi Arabia.
2026-05-18 12:39:52
Geert R. Kersten, CEO of CEL SCI CORP, through The de Clara Trust, purchased 300,000 shares of the company's common stock for $360,000. This insider purchase, occurring on May 14, 2026, increases his indirect holdings and comes amidst recent company activities including a public offering and a distribution agreement for its product Multikine in Saudi Arabia.
